Cutting-edge new research by KellySciPub indicates that the core personalized medicine market will be worth over $60 billion by 2019. This market is made up of companion diagnostics and targeted therapeutics and is currently worth $42 billion.
In my view, the market is set to crash at a certain point in the future. The reason? If the FED...
During the first 11 months of 2014, the industry saw $15.3 billion in venture capital compared...
The June Kaiser Health Tracking Poll found that nearly three-quarters of respondents believed...
Shares of Axovant Sciences nearly doubled in value after the dementia drug developer said its initial public offering raised $315 million, more than Axovant had expected.
The active and diverse treatment pipeline for asthma boasts a striking level of innovation, with many first-in-class products representing significant investment opportunities, says business intelligence provider GBI Research.
The ongoing spat between generic pharmaceutical rivals Teva and Mylan shows no signs of slowing down.
GlobalData’s Healthcare Industry Analyst said as overall healthcare spending has slowed during the recession, new pharmaceutical products and medical technologies have received increased attention regarding their potential cost savings.
A former insurance broker who stole $10 million from Aetna, Inc. by failing to submit health insurance premiums paid by a New Jersey university has pleaded guilty to fraud.
Senior leaders announced plans to file for regulatory approval of more than 10 new products between 2015 and 2019.
Reversing a long-term trend, prices for more than one in four generic medicines widely used by older Americans increased in 2013.
Dyadic International, Inc. is a global biotechnology company focused on enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical, food and feed industries.
Treatment results with the breast cancer drug Herceptin, as well as chemotherapy, did improve, but the drug's backers had been hoping to see better results.
TRACON Pharmaceuticals, a clinical stage biopharmaceutical company, today announced its financial results for the first quarter.
If the Supreme Court rules the way most Republicans want in the latest health overhaul case, GOP lawmakers who now have insurance coverage under President Barack Obama's law may wind up with some explaining to do.
Vitae Pharmaceuticals, a clinical-stage biotechnology company, recently provided financial results and pipeline reports for the first quarter of 2015.
The treatment market value for fibromyalgia across the seven major markets will reach $1.9 billion by 2023, according to research and consulting firm GlobalData.
Novavax, Inc., a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced Q1 results.
Portola Pharmaceuticals today provided a corporate update and reported its financial results for the first quarter.
The global market for Alzheimer’s Disease treatment will more than double in value from $4.9 billion in 2013 to reach an estimated $13.3 billion by 2023.
Amyris, Inc., the industrial bioscience company, today announced financial results for the first quarter of 2015.
Sagent Pharmaceuticals, Inc., a maker of specialty pharmaceutical products with a specific emphasis on the injectable market, today announced financial results for the first quarter.
AMAG Pharmaceuticals, Inc., a specialty pharmaceutical company, today reported unaudited consolidated financial results for the first quarter of 2015.
Pharmaceutical processors face a number of challenges in determining the direction they should take when considering internal investments – but a lack of options have never been amongst them.
Sac-Osage is one of a growing number of rural U.S. hospitals closing their doors, citing a complex combination of factors that have put more financial pressure on facilities.
The most-used medicines in Medicare's prescription drug program are generics, but the program spends the most on brand-name drugs, led by the heartburn treatment Nexium.
TESARO, Inc., an oncology-focused biopharmaceutical company, today reported operating results for first-quarter 2015 and provided an update on the Company's development programs.
The global treatment market value for prostate cancer will expand more than threefold by 2023.
- Page 1